Email Us
Call Us
Altogen Labs announced addition of five new in-house validated xenograft models (4T1, BxPC-3, Calu-6, MDA-MB-468, and PANC-1). This will make a total of 89 CDX xenograft models and 29 PDX xenograft models provided by Altogen Labs. Murine models have been used to investigate human cancer, enabling the discovery and development of new anticancer medicines. Xenograft… Continue Reading
News
Altogen Labs MOLM-13 Leukemia Model Supports FLT3 Inhibitor Development in AML Research
AUSTIN, Texas – March 24, 2018 – Altogen Labs today detailed the research applications of its validated MOLM-13 xenograft model, a robust platform for evaluating FLT3 and HDAC inhibitors in acute myeloid leukemia. The published record demonstrates the model’s utility in the resistance setting. A 2017 study used MOLM-13 to evaluate FF-10101, an irreversible FLT3… Continue Reading
Altogen Labs Stem Cell Services Support Regenerative Medicine Research and Cell Therapy Characterization
AUSTIN, Texas – January 19, 2018 – Altogen Labs today detailed its stem cell services portfolio, supporting researchers and developers working in regenerative medicine and cell-based therapy. The service range covers stem cell collection and processing, screening and isolation techniques, and characterization work supporting both autologous and homologous applications. These pair directly with the company’s… Continue Reading
Altogen Delivery Technology Cited in Regenerative and Aging-Related Gene Modulation Research
AUSTIN, Texas – December 19, 2017 – Altogen delivery technology is cited in Molecular Therapy — Nucleic Acids research on reversing the expression of aging-associated molecules through microRNA transfection, adding regenerative medicine and aging biology to the fields in which the platform appears in the peer-reviewed record. Longevity and regenerative programs face the same preclinical requirements… Continue Reading
Altogen Labs offers xenograft services for drug development of anti-cancer therapeutics
Altogen Labs provides xenograft services for drug development studies of anti-cancer therapeutics by Altogen Labs, Preclinical CRO, 11200 Manchaca Rd, Suite 203 Austin TX 78744 USA (512-433-6177) Contact e-mail: info@altogenlabs.com Introduction Xenograft studies fuels the development of new therapeutics efficiently and effectively and remains the gold standard for preclinical oncology research [1]. Xenograft studies, over… Continue Reading
Altogen Labs: Global Preclinical CRO Advancing Oncology and Drug Development
Altogen Labs is a GLP-compliant global contract research organization (CRO) providing comprehensive preclinical research services to pharmaceutical companies, biotechnology firms, and cancer research institutions worldwide. Headquartered in Austin, Texas, Altogen Labs supports the development of new therapeutics by offering cutting-edge laboratory capabilities in oncology, toxicology, gene expression, and pharmacology. With a focus on accelerating the… Continue Reading
Preclinical Contract Research Studies by Global Health & Pharma
Altogen Labs is a good laboratory practice (GLP) compliant laboratory that provides biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide. Altogen Labs services include safety in vivo toxicology studies (for IND applications), efficacy studies (for regulatory submissions), drug discovery (patent applications), drug development and other types of R&D studies – pharm/tox, bio distribution and imaging studies. Altogen Labs was established in 2009 in Austin,… Continue Reading
Altogen Labs Sarcoma and Prostate Cancer Models Support Rare Tumor and Hormone-Resistance Programs
AUSTIN, Texas – May 11, 2017 – Altogen Labs today detailed its sarcoma and prostate cancer model collections, supporting programs in a rare tumor group and in an indication defined by progression to hormone independence. Sarcomas are rare, biologically diverse, and chronically underserved by preclinical infrastructure. The Altogen Labs collection includes A673 for Ewing sarcoma,… Continue Reading
Altogen Delivery Platform Cited in Nature Medicine Cardiovascular Epigenetics Research
AUSTIN, Texas – December 26, 2016 – Altogen in vivo delivery technology is cited in Nature Medicine research identifying a long noncoding RNA as an epigenetic checkpoint in cardiac hypertrophy, work that demonstrated the platform’s utility well beyond oncology. Cardiac tissue is among the more demanding targets for systemic nucleic acid delivery. Reaching it reproducibly, at… Continue Reading
Altogen Technology Cited in Nature Communications Study of MicroRNA Regulation in Diabetic Kidney Disease
AUSTIN, Texas – November 15, 2016 – Altogen in vivo delivery technology appears among the citations supporting Nature Communications research into microRNA-mediated chromatin remodelling in diabetic nephropathy, extending the documented use of the platform into renal and metabolic disease research. Diabetic kidney disease is a leading cause of end-stage renal failure worldwide, and preclinical progress… Continue Reading